Presentations Given by David Askin

Over the course of his career, David Askin has given dozens of invited presentations on process chemistry and drug development at elite universities and scientific meetings.

  1. “Process Chemistry as an Enabling Technology at Genentech”, Caltech Initiative on Organic Synthesis, California Institute of Technology, Pasadena, CA May 26, 2011.
  2. “Process Chemistry in the Pharmaceutical Industry”, ACS ProSpectives Conference, Boston, MA, Sept 30, 2008.
  3. “From Crixivan® to Isentress®: Process Research Innovation on Merck’s HIV Franchise”, Thirteenth Symposium on the Latest Trends in Organic Synthesis, Brock University, St. Catherines, Ontario, Canada, August 15, 2008.
  4. “From Crixivan® to MK-518: Process Research Innovation on Merck’s HIV Franchise”, Eidgenössische Technische Hochschule, Zürich, Switzerland, September 22, 2006.
  5. “From Crixivan® to MK-518: Process Research Innovation on Merck’s HIV Franchise”, Siegfried Symposium Lecture, University of Zürich, Zürich, Switzerland, September 21, 2006.
  6. “MK-518 and Beyond, First-in-Class”, Harvard University, September 18, 2006.
  7. “Merck’s HIV-1 Integrase Program”, Merck Frosst, Montreal, Canada July 12, 2006.
  8. “Synthesis and Development of an HIV-1 Integrase Inhibitor of Clinical Interest”, 20th International Congress on Heterocyclic Chemistry, Palermo, Italy, August 2, 2005.
  9. “Merck’s HIV-1 Integrase Program”, Isitituto di Ricerca di Biologia Molecolare “P. Angeletti” Pomezia, Rome, Italy, July 28, 2005.
  10. “Synthetically Challenging Molecules of Pharmaceutical Interest in the Treatment of AIDS and other Clinically Urgent Therapeutic Areas”, Brock University, St. Catherines, Ontario, Canada, April 8, 2005.
  11. “Sultam Synthesis via sulfonamide Dianion Alkylation: Application in the Synthesis of Chiral Sultams”, Gordon Conference on Natural Products, Tilton, NH, July 29, 2003.
  12. “Synthesis of a beta-Amino acid Pharmacophore via a ß-Lactam Intermediate”, Gordon Conference on Natural Products, Tilton, NH, July 29, 2004.
  13. “A New Method for the Synthesis of Diversely Functionalized Imidazoles from N-Acylated α–Aminonitriles”, Gordon Conference on Natural Products, Tilton, NH, July 29, 2003.
  14. “Synthetically Challenging Molecules of Pharmaceutical Interest in the Treatment of AIDS, Cancer and Depression”, University of Rochester, Rochester, NY, April 25, 2003.
  15. “Synthetically Challenging Molecules of Pharmaceutical Interest in the Treatment of AIDS, Cancer and Depression”, Montana State University, Bozeman, MT, May 9, 2002.
  16. “Synthetically Challenging Molecules of Pharmaceutical Interest in the Treatment of AIDS, Cancer and Depression”, Johns Hopkins University, Baltimore, MD, September 26, 2001.
  17. “Synthetically Challenging Molecules of Pharmaceutical Interest in the Treatment of AIDS and Cancer”, The Scripps Research Institute, La Jolla, CA, December 1, 2000.
  18. “Synthesis of Imidazole Containing Ras-farnesyltransferase Inhibitors of Clinical Interest”, Gordon Research Conference on Heterocyclic Compounds, Newport, RI, July, 12, 2000.
  19. “Synthetically Challenging Molecules of Pharmaceutical Interest”, Canisius College, Buffalo, NY, October 8, 1999.
  20. “Synthetically Challenging Molecules of Pharmaceutical Interest”, Universite Claude Bernard Lyon, Lyon, France, April 29, 1999.
  21. “Synthetically Challenging Molecules of Pharmaceutical Interest”, Swarthmore University, Swarthmore, PA, April 16, 1998.
  22. “Synthetically Challenging Molecules of Pharmaceutical Interest”, Carnegie Mellon University, Pittsburgh, PA, Feb 24, 1998.
  23. “Synthetically Challenging Molecules of Pharmaceutical Interest”, Gordon Research Conference on Environmentally Benign Synthesis, Oxford, UK, August 17, 1997.
  24. “Asymmetric Synthesis of Indinavir Sulfate”, University of Pittsburgh, Pittsburgh, PA, November 14, 1995.
  25. “Asymmetric Synthesis of Indinavir Sulfate”, Penn State University, University Park, PA, November 13, 1995.
  26. “Diastereoselective Routes to Hydroxyethylene Dipeptide Isosteres: Synthesis of Clinically Interesting HIV-1 Protease Inhibitors”, Duke University, Durham NC, November 4th, 1994.
  27. “Diastereoselective Routes to Hydroxyethylene Dipeptide Isosteres: Synthesis of Clinically Interesting HIV-1 Protease Inhibitors”, University of North Carolina at Chapel Hill, Chapel Hill, NC, November 3rd, 1994.
  28. “Diastereoselective Routes to Hydroxyethylene Dipeptide Isosteres: Synthesis of Clinically Interesting HIV-1 Protease Inhibitors”, Sagami Chemical Research Center, Sagamihara, Japan, September 22nd, 1994.
  29. “Diastereoselective Routes to Hydroxyethylene Dipeptide Isosteres: Synthesis of Clinically Interesting HIV-1 Protease Inhibitors”, Banyu Tsukuba Research Institute, Tsukuba, Japan, September 21st, 1994.
  30. “Diastereoselective Routes to Hydroxyethylene Dipeptide Isosteres: Synthesis of Clinically Interesting HIV-1 Protease Inhibitors”, Tokyo Institute of Technology, Tokyo, Japan, September 20th, 1994.
  31. “Diastereoselective Routes to Hydroxyethylene Dipeptide Isosteres: Synthesis of Clinically Interesting HIV-1 Protease Inhibitors”, Banyu Tokyo Symposium, Tokyo, Japan, September 19, 1994.
  32. “Highly Diastereoselective Reaction of a Chiral, Non-Racemic Amide Enolate with (S)-Glycidyl Tosylate. Synthesis of the Orally Active HIV-1 Protease Inhibitor L-735,524”, University of California Los Angeles, April 28, 1994.
  33. “Highly Diastereoselective Reaction of a Chiral, Non-Racemic Amide Enolate with (S)-Glycidyl Tosylate. Synthesis of the Orally Active HIV-1 Protease Inhibitor L-735,524”, California Institute of Technology, April 27, 1994.
  34. “Highly Diastereoselective Reaction of a Chiral, Non-Racemic Amide Enolate with (S)-Glycidyl Tosylate. Synthesis of the Orally Active HIV-1 Protease Inhibitor L-735,524”, Case Western Reserve University, October 7, 1993.
  35. “HIV Protease Inhibitors: New Synthetic Routes to Hydroxyethylene Dipeptide Isosteres”, University of Kansas, April 30, 1992.
  36. “HIV Protease Inhibitors: New Synthetic Routes to Hydroxyethylene Dipeptide Isosteres”, Boston University, November 25, 1991.
  37. “HIV Protease Inhibitors: New Synthetic Routes to Hydroxyethylene Dipeptide Isosteres”, Merck Centennial Lecture, Yale University, November 14, 1991.
  38. “HIV Protease Inhibitors: New Synthetic Routes to Hydroxyethylene Dipeptide Isosteres”, Gordon Research Conferences on Natural Products, July 24, 1991.
  39. “Total Synthesis and Chemistry of the Immunosuppressant (-)-FK-506″, Yale University, October 12, 1989.
  40. “Total Synthesis and Chemistry of the Immunosuppressant (-)-FK-506″, University of Michigan, Ann Arbor, MI, May 3, 1989.
  41. “Total Synthesis of the Immunosuppressant (-)-FK-506″, Rice University, Houston, TX, February 21, 1989.
  42. “Total Synthesis of the Immunosuppressant (-)-FK-506″, University of Houston, Houston, TX, February 20, 1989.
  43. “Alkylation of Chiral Prolinol Propionamide Enolates with Epoxides: Application to FK-506 Synthesis”, 1988 Gordon Research Conference on Natural Products, New Hampton, NH, July 1988.
  44. “A Total Synthesis of N-Acetylactinobolamine”, 1985 Gordon Research Conference on Natural Products, New Hampton, NH, July 1985.